RGNX Seeks FDA Approval
REGENXBIO plans to resubmit its one-time gene therapy for Hunter Syndrome to the FDA after a path forward was established.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.